Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 2
September 10, 2015
- Drug Pricing Tomorrow: MOF Budget Examiner Eyes “Sharp Price Cuts” for Both New and Listed Generics in 2016
September 9, 2015
- MHLW Launches Office to Promote Genomic Medicine
September 9, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 1
September 9, 2015
- Research-Driven Makers Need Enough Capital Strength to Withstand Discontinuation of R&D Projects: Comprehensive Strategy
September 8, 2015
- Can’t Give Timeline for Active Recommendation for HPV Vaccines, Expert Discussions Eyed: Govt
September 8, 2015
- Notification Service for Generic Use Saves 15.8 Billion Yen in Medical Spending in FY2014: Kyokai Kenpo
September 8, 2015
- MHLW Announces Comprehensive Strategy to Beef Up Pharma Industry, Vows to Promote Reward for Innovation
September 7, 2015
- Japan Medical Spending Hits Another Record in FY2014, Year-End Generic Share at 58.4%: MHLW
September 7, 2015
- MEXT Funding Research Project to Propose New Business Models and Financing Methods to Promote Drug Development
September 4, 2015
- PAFSC Committee Recommends Approval for 2 Regenerative Medicine Products
September 4, 2015
- PMDA to Select Products for Sakigake Review; “Probably 5 to 10” Will Be Designated: Official
September 3, 2015
- 5 Companies Find 46 Unreported ADR Cases as a Result of Self-Inspections
September 3, 2015
- Ryukaikon Calls for Elimination of Medical Fee Cut Rule for Low Price Settlement Rates Once Early Price Settlements Are Achieved
September 2, 2015
- Ryukaikon Submits New Proposal to Improve Drug Distribution Environment
September 2, 2015
- AbbVie’s Hep C Drug OK’ed by PAFSC Committee, Setting Stage for Competition with Harvoni
September 1, 2015
- PAFSC First Committee Backs Approval of Glatiramer, Add’l Indication for Xarelto
August 31, 2015
- FY2016 Budget Request to Earmark 151.5 Billion Yen for AMED, with 25.3 Billion Yen for Drug Discovery and Development
August 31, 2015
- METI Seeks 126.9 Billion Yen in FY2016 Budget for Science, Technology Promotion, 21.2 Billion Yen for AMED
August 31, 2015
- MEXT Seeks 5.86 Trillion in FY2016 Budget for “Innovative Drug Discovery for Cancer”
August 31, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…